Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001610618-22-000089
Filing Date
2022-11-29
Accepted
2022-11-29 16:20:14
Documents
2

Document Format Files

Seq Description Document Type Size
1 DEFINITIVE ADDITIONAL MATERIALS cdtxdefa14a2022-11.htm DEFA14A 23061
2 GRAPHIC cdtxlogoa13.jpg GRAPHIC 46741
  Complete submission text file 0001610618-22-000089.txt   83324
Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Filer) CIK: 0001610618 (see all company filings)

EIN.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36912 | Film No.: 221433037
SIC: 2836 Biological Products, (No Diagnostic Substances)